• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Apollomics Inc.

    5/20/24 4:15:32 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLM alert in real time by email
    SC 13G 1 ea0206549-13gmaxpro_apollo.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    Apollomics Inc.

    (Name of Issuer)

     

    Class A ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    G0411D107

    (CUSIP Number)

     

    May 8, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G0411D107 Schedule 13G Page 2 of 6

     

    (1)

    NAMES OF REPORTING PERSON

     

    Maxpro Investment Co., Ltd

    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
       
      (a) ☐
      (b) ☐
    (3) SEC USE ONLY
       
       
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    (5) SOLE VOTING POWER
       
      10,507,040 (1)
    (6) SHARED VOTING POWER
       
      0
    (7) SOLE DISPOSITIVE POWER
       
      10,507,040 (1)
    (8) SHARED DISPOSITIVE POWER
         
        0

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      10,507,040 (1)
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
       
       
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
       
      9.64% (2)
    (12) TYPE OF REPORTING PERSON
       
      FI

     

    (1) Maxpro Investment Co., Ltd may be deemed to beneficially own 10,507,040 Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”) of Apollomics Inc. (the “Issuer”), consisting of (i) 10,124,645 Class A Ordinary Shares and (ii) 382,395 Class A Ordinary Shares issuable upon exercise of warrants exercisable within 60 days of the date of this filing.
    (2) On April 24, 2024, the Issuer had 89,495,790 Class A Ordinary Shares issued and outstanding, as reported in the Issuer’s Rule 424(b)(3) Prospectus, filed with the Securities and Exchange Commission (the “SEC”) on April 24, 2024. On May 8, 2024, the Issuer issued 19,166,666 Class A Ordinary Shares in a private placement with certain accredited investors. Calculations are based on a total of 108,662,456 Class A Shares issued and outstanding as of the date of this filing.

     

     

     

     

    CUSIP No. G0411D107 Schedule 13G Page 3 of 6

     

    Item 1(a). Name of Issuer:

     

    Apollomics Inc. (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    989 E. Hillsdale Blvd., Suite 220,

    Foster City, CA 94404

     

    Item 2(a). Name of Person Filing:

     

    Maxpro Investment Co., Ltd (the “Reporting Person”)

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    5F-4, No.89, Songren Rd., Xinyi District., Taipei City, Taiwan 11073

     

    Item 2(c). Citizenship:

     

    Cayman Islands

     

    Item 2(d). Title of Class of Securities:

     

    Class A ordinary shares, par value $0.0001 per share (“Class A Ordinary Shares”) 

     

    Item 2(e). CUSIP Number:

     

    G0411D107

     

    Item 3. If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act;
         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act;
         
    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act;
         
    (d) ☐ Investment company registered under Section 8 of the Investment Company Act;
         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance Rule 13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;.
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
         
    (j) ☒ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ______

     

     

     

     

    CUSIP No. G0411D107 Schedule 13G Page 4 of 6

     

    Item 4. Ownership:

     

    Information with respect to the beneficial ownership of securities of the Reporting Person, is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

     

    As reported in the cover page to this report, the ownership information with respect to the Reporting Person is as follows:

     

    (a)Amount Beneficially Owned: See line 9 of page 2.

     

    (b)Percent of Class: See line 11 of page 2.

     

    (c)Number of Shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote: See line 5 of page 2.

     

    (ii)Shared power to vote or to direct the vote: See line 6 of page 2.

     

    (iii)Sole power to dispose or to direct the disposition of: See line 7 of page 2.

     

    (iv)Shared power to dispose or to direct the disposition of: See line 8 of page 2.

     

    As of the date of this filing, the Reporting Person may be deemed to beneficially own 10,507,040 Class A ordinary Class A Ordinary Shares, consisting of (i) 10,124,645 Class A Ordinary Shares and (ii) 382,395 Class A Ordinary Shares issuable upon exercise of warrants exercisable within 60 days of the date of this filing, constituting approximately 9.64% of the issued and outstanding Class A Ordinary Shares of the Issuer (the “Shares”).

      

    The filing of this Schedule 13G shall not be construed as an admission that the Reporting Person, or any of its subsidiaries or affiliates, is or are the beneficial owners of the Shares for any other purpose than Section 13(d) and 13(g) of the Act, as amended.

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

      

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group:

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group:

     

    Not Applicable.

     

     

     

     

    CUSIP No. G0411D107 Schedule 13G Page 5 of 6

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to an investment company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

     

     

     

    CUSIP No. G0411D107 Schedule 13G Page 6 of 6

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete, and correct.

     

    Date: May 20, 2024

     

      /s/ Yi Kuei Chen
      Name:  Yi Kuei Chen
      Title: Director

     

     

     

     

    Get the next $APLM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APLM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APLM
    SEC Filings

    See more
    • SEC Form 20-F filed by Apollomics Inc.

      20-F - Apollomics Inc. (0001944885) (Filer)

      4/3/25 4:51:31 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Apollomics Inc.

      6-K - Apollomics Inc. (0001944885) (Filer)

      4/3/25 4:40:55 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Apollomics Inc.

      6-K - Apollomics Inc. (0001944885) (Filer)

      3/31/25 8:00:45 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

      Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification$9.8 million in cash and cash equivalents as of December 31, 2024, in conjunction with LaunXP upfront payment, pipeline focus and expense reductions expected to provide cash runway into the first quarter of 2026 FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical bio

      4/3/25 4:05:00 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

      LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer ("NSCLC")Apollomics to receive upfront payments of $10 million, and is eligible for pre-commercial milestones up to $50 million, and royalties on net product sales FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co.,

      3/31/25 8:00:32 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

      FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan. The Phase 3 trial was a randomized, double-blinded bridging trial to evaluate the safety and efficacy of uproleselan administered with chemotherapy versus chemotherapy alone in patients with relapsed or refract

      12/20/24 8:00:00 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

      SC 13D/A - Apollomics Inc. (0001944885) (Subject)

      8/15/24 4:38:25 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

      SC 13G/A - Apollomics Inc. (0001944885) (Subject)

      5/30/24 4:15:08 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

      SC 13D/A - Apollomics Inc. (0001944885) (Subject)

      5/22/24 7:32:01 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLM
    Financials

    Live finance-specific insights

    See more
    • Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

      Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-

      3/28/24 7:00:00 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

      FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co

      3/26/24 8:00:00 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

      Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou

      9/28/23 4:17:57 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care